This one appears in the most recent issue of “International Journal of Molecular Sciences” (Q1 Medicine).
The paper highlights the qualities of two clinically approved-drugs for autoimmune disease, Fingolimod and Dimethyl Fumarate (DMF), in reducing tumors in lung cancer using in vitro and in vivo models. This work suggests the merits of further evaluation of Fingolimod and DMF as a potential therapeutic for lung cancer. A variety of methodologies and techniques were used including 3D spheroid models and allograft/xenograft mouse models.
Here is a direct link to the paper: https://lnkd.in/eHU4sFvT